Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis forU.S./Canada Rights to Novel Epinephrine Auto-injector

Mon, 11/30/2009 - 3:40am
Intelliject, Inc. today announcedan exclusive license with sanofi-aventis U.S. for a novel epinephrineauto-injector, in the U.S. and Canada territory. Under the license,sanofi-aventis U.S. shall be responsible for manufacturing andcommercialization. Intelliject will be responsible for the on-goingdevelopment and for obtaining U.S. regulatory approval and has retainedcertain co-promotion rights in the territory. Sanofi-aventis U.S. will pay an initial upfront payment of $25 million.Intelliject will also be eligible to receive development and commercialmilestones of up to $205 million as well as tiered double-digit royalties onsales of any products commercialized under the license. "We are delighted to have sanofi-aventis U.S. as our partner with theirproven track record in and commitment to the allergy/immunology area. Thispartnership marks a key milestone in our quest to make our novel epinephrineauto-injector available to the millions of patients at risk for anaphylaxis.We expect it to create significant long-term value for the company; it marksthe first step on our mission to bring the same innovation and patient-centricsolutions to many different therapy areas. Intelliject's unique model -- drugdevelopment expertise combined with a proprietary, patient-centric deliveryplatform -- has the potential to dramatically redefine the "Standard of Care"in multiple biopharmaceutical categories," said Spencer Williamson, Presidentand CEO of Intelliject.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.